EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudie

Safety of Tenecteplase in Stroke Mimics Compared With Acute Ischemic Stroke: A Retrospective Cohort Study

A Shaun Rowe iD, Brian Wiseman, Leslie A Hamilton iD, Sarah Crowell, Lillian McCampbell, Destiny Ford

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-01 · 46 (1)

DOI: 10.1002/phar.70112 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 22.01.2026. Verfasst von A Shaun Rowe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Knoxville, Tennessee, USA. Hauptthemen laut MEDLINE: Tenecteplase, Ischemic Stroke, Fibrinolytic Agents, Intracranial Hemorrhages. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute ischemic stroke (AIS) accounts for 87% of all strokes and is associated with high morbidity and mortality. Stroke mimics, conditions that present with stroke‐like symptoms but are not AIS, represent an important proportion of stroke cases. Tenecteplase, an alteplase variant with higher fibrin affinity and a longer half‐life, has recently gained approval for the treatment of AIS. Limited evidence exists on the safety of tenecteplase in stroke mimics.

Objective

The objective of this study was to determine the incidence of intracranial hemorrhage in patients with stroke‐like signs and symptoms who received tenecteplase with and without a confirmed diagnosis of AIS.

Methods

This was a single‐center, retrospective cohort study conducted at a comprehensive stroke center. Patients who received tenecteplase for stroke‐like symptoms from June 2020 to December 2021 were included. Patients were grouped based on AIS diagnosis confirmed by neuroimaging or discharge diagnosis. The primary outcome was the incidence of intracranial hemorrhage, and secondary outcomes included incidence of symptomatic and asymptomatic intracranial hemorrhage, extracranial hemorrhage, hospital length of stay, angioedema development, and discharge disposition.

Results

Of 250 patients, 174 were diagnosed with AIS and 76 with stroke mimics. Patients with AIS were older (69 years [SD: 13.8 years] vs. 62.3 years [SD: 16.1 years]; p = 0.0008), had higher hypertension prevalence (132 [75.9%] vs. 44 [57.9%]; p = 0.0042), and lower previous stroke prevalence (9 [5.2%] vs. 11 [14.5%]; p = 0.0126) compared with stroke‐mimic patients, respectively. Patients with AIS had shorter median tenecteplase door‐to‐needle times (38.5 min [IQR: 30 min, 53 min] vs. 46.5 min [IQR: 34.5 min, 64.5 min]; p = 0.0154) compared with stroke mimics. Intracranial hemorrhage occurred in 11.5% of patients with AIS and none in stroke mimics ( p = 0.0021). Symptomatic hemorrhage rates were similar between groups. Patients with AIS had longer median hospital stays (3 days [IQR: 2 days, 6 days] vs. 2 days [IQR: 2 days, 4 days]; p = 0.0018). Discharge dispositions and cases of angioedema were similar between groups.

Conclusion

Tenecteplase appears safe for stroke mimics, with no disproportionate harm compared to patients with AIS. This study further supports the safety of tenecteplase in stroke mimics, aiding rapid treatment decisions in stroke‐like presentations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenecteplaseIschemic StrokeFibrinolytic AgentsIntracranial HemorrhagesStrokeHumansRetrospective StudiesFemaleAgedMaleMiddle AgedIncidenceTissue Plasminogen ActivatorCohort StudiesAged, 80 and overLength of StayBrain Ischemia

Stichwörter der Autor:innen

intracranial hemorrhageretrospective studysafetystrokestroke mimictenecteplase

Substanzen

TenecteplaseFibrinolytic AgentsTissue Plasminogen Activator

Autor:innen und Institutionen

  • Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Knoxville, Tennessee, USA.
  • Internal Medicine, Neurology Division, University of Tennessee Health Science Center Graduate School of Medicine, Knoxville, Tennessee, USA.

ORCID-Profile: A Shaun Rowe, Leslie A Hamilton

Zitieren

APA

Rowe, A. S., Wiseman, B., Hamilton, L. A., Crowell, S., McCampbell, L., & Ford, D. (2026). Safety of Tenecteplase in Stroke Mimics Compared With Acute Ischemic Stroke: A Retrospective Cohort Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(1). https://doi.org/10.1002/phar.70112

Vancouver

Rowe AS, Wiseman B, Hamilton LA, Crowell S, McCampbell L, Ford D. Safety of Tenecteplase in Stroke Mimics Compared With Acute Ischemic Stroke: A Retrospective Cohort Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(1). doi:10.1002/phar.70112

BibTeX
@article{Rowe2026,
  author = {Rowe, A Shaun and Wiseman, Brian and Hamilton, Leslie A and Crowell, Sarah and McCampbell, Lillian and Ford, Destiny},
  title = {Safety of Tenecteplase in Stroke Mimics Compared With Acute Ischemic Stroke: A Retrospective Cohort Study},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  volume = {46},
  number = {1},
  doi = {10.1002/phar.70112}
}
Kostenlos starten →